Guangdong Academy of Medical Sciences
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
2011 · Caicun Zhou, Yi−Long Wu, et al. · The Lancet Oncology
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 · Tony Mok, Yi−Long Wu, et al. · New England Journal of Medicine
Lung cancer: current therapies and new targeted treatments
2016 · Fred R. Hirsch, Giorgio V. Scagliotti, et al. · The Lancet